Editorial Renal denervation after the symplicity HTN-3 trial

Ewa Warchoł-Celińska; Andrzej Januszewicz; Aleksander Prejbisz; Jacek Kądziela

doi:10.5114/pwki.2014.43509

January 1, 2014Advances in Interventional CardiologyOpen Access

Editorial Renal denervation after the symplicity HTN-3 trial

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does renal nerve ablation reduce systolic blood pressure in patients with treatment-resistant hypertension?

Structured PICO

Does renal nerve ablation reduce systolic blood pressure in patients with treatment-resistant hypertension?

P

Population

535 patients with treatment-resistant hypertension (systolic BP ≥ 160 mm Hg despite concurrent use of three antihypertensive drugs including a diuretic at maximally tolerated dosages, daytime SBP average ≥ 135 mm Hg)

I

Intervention

Renal nerve ablation using the Symplicity Flex Catheter

C

Comparator

Renal angiography only (sham control)

O

Outcome

Change in office systolic blood pressure (SBP) at 6 monthssurrogate

Limitations

Inexperienced operators (around 3 procedures per operator)
No test available to assess proper wall contact and effective destruction of renal nerves
High percentage of patients on direct-acting vasodilators and aldosterone antagonists
Relatively short follow-up of 6 months to assess placebo effect decline

Implication

The Symplicity HTN-3 trial demonstrated that renal denervation did not significantly reduce office or ambulatory systolic blood pressure compared to a sham procedure in patients with resistant hypertension, challenging previous unblinded trial results.

Abstract

AMA Warchoł-Celińska E, Januszewicz A, Prejbisz A, Kądziela J. EditorialRenal denervation after the symplicity HTN-3 trial. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2014;10(2):75-77. doi:10.5114/pwki.2014.43509. APA Warchoł-Celińska, E., Januszewicz, A., Prejbisz, A., & Kądziela, J. (2014). EditorialRenal denervation after the symplicity HTN-3 trial. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 10(2), 75-77. https://doi.org/10.5114/pwki.2014.43509 Chicago Warchoł-Celińska, Ewa, Andrzej Januszewicz, Aleksander Prejbisz, and Jacek Kądziela. 2014. "EditorialRenal denervation after the symplicity HTN-3 trial". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 10 (2): 75-77. doi:10.5114/pwki.2014.43509. Harvard Warchoł-Celińska, E., Januszewicz, A., Prejbisz, A., and Kądziela, J. (2014). EditorialRenal denervation after the symplicity HTN-3 trial. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 10(2), pp.75-77. https://doi.org/10.5114/pwki.2014.43509 MLA Warchoł-Celińska, Ewa et al. "EditorialRenal denervation after the symplicity HTN-3 trial." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 10, no. 2, 2014, pp. 75-77. doi:10.5114/pwki.2014.43509. Vancouver Warchoł-Celińska E, Januszewicz A, Prejbisz A, Kądziela J. EditorialRenal denervation after the symplicity HTN-3 trial. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2014;10(2):75-77. doi:10.5114/pwki.2014.43509.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Warchoł-Celińska et al. (2014) studied this question.

synapsesocial.com/papers/6a84ae672cc9708cfc15add4 https://doi.org/10.5114/pwki.2014.43509

View Full Paper

Ask AI

Bookmark

Share

Editorial Renal denervation after the symplicity HTN-3 trial

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Editorial Renal denervation after the symplicity HTN-3 trial

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading